Key:
C = CALGB
E = ECOG
N = NSABP
P = Pharmacy
R = RTOG
S = SWOG
CTSU= NCI Cancer Trials Support Unit
V = Vermont Cancer Center
Updated 4-28-11
Bladder:
C 90601
- A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
Bone:
VCC 1012
- Loratadine for treatment of Pegfilgrastim-induced bone pain.
Breast:
N B43
- A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
N B46
- A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
N B47
- A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (6 Cycles of Docetaxel Plus Cyclophosphamide or 4 Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
C 40502
- A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone combined with bevacizumab as 1st line therapy for locally recurrent or metastatic breast cancer
C 40603
- Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer.
C 70806
- Vitamin D and Breast Cancer Biomarkers
CTSU E3108
- A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
CTSU N0733
- Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
CTSU S0800
- A Randomiized Phase II Trial of weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed By Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) As Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer
CTSU S1007
- A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with
Recurrence Score (RS) of 25 or Less
Colorectal:
C 80702
- A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
CTSU N0949
- Randomized Phase III Trial of mFOLFOX7 or XELOX Plus BevacizumabVersus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer
Gastric/Gastroestroesophageal:
CTSU-RTOG-0436
- Phase III Trial evaluating the addition of Cetuximab to Paclitaxel, Cisplatin and RT for Patients with esophageal cancer who are treated without surgery
CTSU-RTOG-1010
- A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Head & Neck:
CTSU E-1305
- A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer
CTSU RTOG-0920
- A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Liver:
C 80802
- Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).
Lung: SCLC Limited:
C 30610
- Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Lung: SCLC Extensive:
C 30504
- Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study
Lung: NSCLC Limited:
CTSU-E1505
- A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
Lung: NSCLC Stage III:
C 30605
- A Phase II Study of Induction Chemotherapy followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-small Cell Lung Cancer
***Temp. Suspension***
Lung: NSCLC Advanced:
C 30607
- Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
C 30801
- A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
CTSU-S0819
- A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer
CTSU-E5508
- A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Lymphoma:
C 50303
- Phase III randomized study of R-CHOP vs. dose-adjusted EPOCH-R with molecular profiling in untreated DeNovo diffuse large B-cell lymphomas
MDS:
CTSU E2905
- Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Melanoma:
CTSU E1609
- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy vs. High-Dose Interferon α-2b for Resected High-Risk Melanoma
Other:
C 70604
- A randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Pancreas:
C 80701
- Randomized Phase II Study of Everolimus Alone versus Everolimus plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
RTOG-0848
- A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Prostate:
CTSU E-3805
- CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer
Renal:
CTSU S0931
- EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
C-90802
- Randomized phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal cell carcinoma progressing after treatment with tyrosine kinase inhibitors
Prevention Trials:
N P-5
- Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
